

# A Randomized Trial Comparing Same Day Discharge and a Single Bolus of Abciximab to Overnight Hospitalization and Bolus + Perfusion Abciximab After Uncomplicated Trans-Radial Coronary Artery Stenting

<b>Submission date</b> 05/01/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 04/02/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 18/10/2007	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Olivier Bertrand

**Contact details**  
2725 Chemin Ste Foy  
Quebec  
Canada  
G1V 4G5  
+1 418 656 8711 ext 3136  
olivier.bertrand@crhl.ulaval.ca

## Additional identifiers

**ClinicalTrials.gov (NCT)**  
NCT00169819

**Protocol serial number**  
H4S-CA-0050

# Study information

## Scientific Title

### Acronym

EARly discharge after trans-radial Stenting of coronarY arteries: The EASY study

### Study objectives

1. Discharge on the same day after uncomplicated trans-radial coronary artery stenting is safe and effective.
2. Hospitalized patients can be safely returned to the referring center the same day following trans-radial coronary artery stenting.
3. Abciximab given as a single bolus with optimal trans-radial coronary artery stenting is as safe and effective as bolus + 12 hrs perfusion and does not hamper early discharge.
4. Same-day discharge is cost-effective and increases patient satisfaction.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Study type(s)

Treatment

### Health condition(s) or problem(s) studied

Angina

### Interventions

Patients with stable or unstable angina referred for catheterization and possible percutaneous intervention are eligible.

After diagnostic trans-radial catheterization, patients receive a bolus of Abciximab and undergo dilatation and stent implantation. At the end of the uncomplicated procedure, patients are randomized between group 1: No perfusion of Abciximab and discharge 4-6 hours after PCI and group 2: Standard 12 hours Abciximab perfusion and overnight hospitalization. In case of complications, patients are included in a registry and receive standard 12 hours Abciximab perfusion. Electrocardiogram (ECG) and biology tests (creatinine kinase [CK] CK-myocardial band [CK-MB], troponins) are performed before, 4-6 hours after and the next day after PCI. Clinical follow-up is performed at 24 hours, 30 days, 6 months and 1 year after PCI.

### Intervention Type

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Abciximab

**Primary outcome(s)**

The primary end-point of the study is the composite of death, myocardial infarction, repeat hospitalization, urgent revascularization, severe thrombocytopenia, access site complications and major bleedings at 30 days following stent implantation.

**Key secondary outcome(s)**

The secondary end-point is the composite of death, myocardial infarction, repeat target vessel revascularization at 30 days, 6 months and 1 year following stent implantation. Other secondary end-points include the total hospital stay (days) between the index procedure and the first 30 days follow-up, the number of unsolicited medical visits in relation with the percutaneous procedure, index of patient satisfaction and direct and indirect costs.

**Completion date**

29/04/2005

**Eligibility****Key inclusion criteria**

Approximately 1000 patients undergoing 'ad hoc' percutaneous coronary intervention (PCI) will be randomized.

**Inclusion Criteria:**

1. Patients with documented ischemic coronary artery disease and scheduled for possible coronary artery stenting are eligible.
2. Patient must be >18 years of age.
3. Patient and treating interventional cardiologist agree for randomization.
4. Patient will be informed of the randomization process and will sign an informed consent.
5. Diagnostic and therapeutic intervention performed through trans-radial/ulnar artery approach.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

## **Key exclusion criteria**

### **CLINICAL:**

1. Patients with recent (<72 hrs) Q-wave (ST elevation) acute myocardial infarction
2. History of LV ejection fraction  $\leq 30\%$
3. Unstable clinical condition
4. Any complication compromising ambulation
5. Concurrent participation in other investigational study requiring prolonged hospitalization
6. Required prolonged hospitalization
7. In cath lab transient vessel closure
8. Resuscitation per PCI
9. Hemodynamic collapse during PCI
10. Severe entry site complication upon investigator decision
11. Social isolation
12. Serious cognitive disorders
13. Femoral sheath (artery)
14. Persisting chest pain
15. No ASA prior PCI
16. Allergy to ASA or thienopyridines precluding treatment for 30 days
17. Any significant blood dyscrasia
18. PCI without stent implantation (except for bifurcation lesion or re-dilatation for in-stent restenosis)
19. International Normalised Ratio (INR)  $>2.0$
20. Contraindication to Reopro administration

### **ANGIOGRAPHIC:**

1. Residual dissection of grade  $\geq B$  of NHBLI classification
2. Compromised or sub-occluded branch with diameter  $\geq 1$  mm
3. Timi  $<3$  post-stenting
4. Thrombus post-PCI

### **Date of first enrolment**

15/10/2003

### **Date of final enrolment**

29/04/2005

## **Locations**

### **Countries of recruitment**

Canada

### **Study participating centre**

2725 Chemin Ste Foy

Quebec

Canada

G1V 4G5

# Sponsor information

## Organisation

Laval Hospital Research Center (Canada)

## Funder(s)

### Funder type

Industry

### Funder Name

This Study is an Investigator Initiated Trial, which is supported by unrestricted grants from Eli-Lilly and Bristol-Myers-Squibb (Canada)

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	Results	12/12/2006		Yes	No